Yahoo Finance29d
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia. The launch of our non-GLP study in December 2024 marked the ...
Business Insider29d
Silo Pharma announces initial data from SP-26 study
Silo Pharma (SILO) announced am update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously.
manilatimes1mon
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia. The launch of our non-GLP study in December 2024 marked the first ...
The Bakersfield Californian1mon
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.